Longeveron (LGVN) News Today $1.70 +0.15 (+9.68%) Closing price 03/12/2025 04:00 PM EasternExtended Trading$1.68 -0.02 (-1.18%) As of 03/12/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Roth MKM Keeps Their Buy Rating on Longeveron (LGVN)March 12 at 12:19 AM | markets.businessinsider.comLongeveron Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B) in Alzheimer's DiseaseMarch 11 at 7:19 PM | finanznachrichten.deLongeveron announces publication of results of Phase 2a trial of Lomecel-BMarch 11 at 7:19 PM | markets.businessinsider.comLongeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer's DiseaseMarch 11 at 8:30 AM | globenewswire.comWhat is HC Wainwright's Estimate for Longeveron Q1 Earnings?March 7, 2025 | americanbankingnews.comFY2025 EPS Estimates for Longeveron Cut by Zacks Small CapMarch 7, 2025 | americanbankingnews.comQ1 Earnings Estimate for Longeveron Issued By Roth CapitalMarch 7, 2025 | americanbankingnews.comLongeveron® to Present at the 37th Annual Roth ConferenceMarch 5, 2025 | globenewswire.comHC Wainwright Reaffirms Buy Rating for Longeveron (NASDAQ:LGVN)March 5, 2025 | americanbankingnews.comRoth MKM Sticks to Its Buy Rating for Longeveron (LGVN)March 4, 2025 | markets.businessinsider.comLongeveron Inc. Earnings Call: Growth and ChallengesMarch 3, 2025 | tipranks.comLGVN Well Positioned for Critical 2025March 3, 2025 | msn.comLongeveron Inc. (NASDAQ:LGVN) Q4 2024 Earnings Call TranscriptMarch 3, 2025 | insidermonkey.comEarnings call transcript: Longeveron Q4 2024 sees revenue surge, stock gainsMarch 2, 2025 | investing.comAnalysts Expect Breakeven For Longeveron Inc. (NASDAQ:LGVN) Before LongMarch 2, 2025 | finance.yahoo.comLongeveron reports Q4 revenue $700,000, consensus $637,500March 1, 2025 | markets.businessinsider.comLongeveron Inc. (LGVN) Q4 2024 Earnings Call TranscriptFebruary 28, 2025 | seekingalpha.comLongeveron® Announces Full-Year 2024 Financial Results and Provides Business UpdateFebruary 28, 2025 | globenewswire.comLongeveron management to meet with MaximFebruary 26, 2025 | markets.businessinsider.comLongeveron® Announces World Health Organization Approval of "laromestrocel" as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™February 18, 2025 | tmcnet.comLongeveron’s Lomecel receives WHO non-proprietary name approval as laromestroceFebruary 18, 2025 | markets.businessinsider.comLongeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™February 18, 2025 | globenewswire.comLongeveron announces board member resignationJanuary 31, 2025 | msn.comLongeveron to Present at Biotech Showcase 2025December 18, 2024 | globenewswire.comRoth MKM Initiates Coverage of Longeveron (LGVN) with Buy RecommendationDecember 6, 2024 | msn.comLongeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024December 2, 2024 | globenewswire.comLongeveron Buy Rating Affirmed: Promising Clinical Developments and Strong Financial PositionNovember 26, 2024 | markets.businessinsider.comLongeveron Inc. (LGVN) Latest Stock News & Headlines - Yahoo FinanceNovember 24, 2024 | finance.yahoo.comLGVN Highlights Potential Groundbreaking TreatmentsNovember 13, 2024 | msn.comA Look Ahead: Longeveron's Earnings ForecastNovember 13, 2024 | benzinga.comLongeveron® Announces Third Quarter 2024 Financial Results and Provides Business UpdateNovember 13, 2024 | finance.yahoo.comLongeveron, Inc. (LGVN) Q3 2024 Earnings Call TranscriptNovember 12, 2024 | seekingalpha.comEarnings To Watch: Longeveron Inc (LGVN) Reports Q3 2024 ResultNovember 11, 2024 | finance.yahoo.comLongeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC)November 11, 2024 | globenewswire.comPromising Prospects for Lomecel-B: A Buy Recommendation Based on Positive Clinical Data and Regulatory PotentialNovember 5, 2024 | markets.businessinsider.comLongeveron® to Report Third Quarter 2024 Financial Results and Host Conference Call on November 12, 2024November 4, 2024 | globenewswire.comLongeveron presents Alzheimer's therapy data at CTAD24October 31, 2024 | investing.comLongeveron® Presents Lomecel-B™ Data for Alzheimer's Disease Indication in Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)October 29, 2024 | globenewswire.comLongeveron presents Lomecel-B long-term transplant-free survival data in HLHSOctober 29, 2024 | markets.businessinsider.comLGVN Announces Treatment Garners Excellent ResultsOctober 29, 2024 | msn.comLongeveron® Presents Lomecel-B™ Long-term Transplant-free Survival Data in Hypoplastic Left Heart Syndrome (HLHS) at the Congenital Heart Surgeons' Society (CHSS) 51st Annual MeetingOctober 27, 2024 | globenewswire.comLongeveron® Lomecel-B™ Data in Alzheimer's Disease Selected for Late Breaking Poster Presentation at the Clinical Trials on Alzheimer's Disease Conference (CTAD24)October 14, 2024 | globenewswire.comLongeveron® Lomecel-B™ 5-Year Long-term Transplant-free Survival Data in HLHS Selected for Oral Presentation at the Congenital Heart Surgeons' Society (CHSS) 51st Annual MeetingOctober 9, 2024 | globenewswire.comLongeveron® to Present at the UBS Virtual Organ Restoration and Cell Therapy DayOctober 7, 2024 | globenewswire.comLongeveron (NASDAQ:LGVN) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comLongeveron® to Participate in the 3rd Annual ROTH Healthcare Opportunities ConferenceOctober 2, 2024 | globenewswire.comBioMedNewsBreaks — Longeveron Inc. (NASDAQ: LGVN) to Participate at the Cell & Gene Meeting on the MesaSeptember 27, 2024 | msn.comLongeveron to Attend Alliance for Regenerative Medicine’s Cell & Gene Meeting on the MesaSeptember 26, 2024 | finance.yahoo.comLongeveron to Attend Alliance for Regenerative Medicine's Cell & Gene Meeting on the MesaSeptember 26, 2024 | globenewswire.comBuy Rating Affirmed for Longeveron on Favorable Lomecel-B Regulatory Outlook and Trial ProgressSeptember 4, 2024 | markets.businessinsider.com Remove Ads Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Email Address LGVN Media Mentions By Week LGVN Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LGVN News Sentiment▼0.530.75▲Average Medical News Sentiment LGVN News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LGVN Articles This Week▼202▲LGVN Articles Average Week Remove Ads Get Longeveron News Delivered to You Automatically Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies LXEO News CABA News DBVT News ANL News SCLX News RANI News ANIX News CRBP News SLS News IFRX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LGVN) was last updated on 3/13/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredThe real reason gold is soaring (and likely to continue)Trump’s Policies Are Fueling a Gold Boom—Here’s Your Chance to Profit Donald Trump’s bold policies are driv...Golden Portfolio | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Longeveron Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Longeveron With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
